Jefferies Financial Group Inc. Takes Position in Dianthus Therapeutics, Inc. $DNTH

Jefferies Financial Group Inc. bought a new stake in shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) during the 2nd quarter, according to its most recent filing with the SEC. The firm bought 5,886 shares of the company’s stock, valued at approximately $574,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of DNTH. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Dianthus Therapeutics by 4.2% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,334 shares of the company’s stock worth $280,000 after acquiring an additional 618 shares during the period. American Century Companies Inc. raised its stake in shares of Dianthus Therapeutics by 13.2% during the second quarter. American Century Companies Inc. now owns 54,140 shares of the company’s stock valued at $1,009,000 after purchasing an additional 6,323 shares during the period. Invesco Ltd. raised its stake in shares of Dianthus Therapeutics by 31.1% during the second quarter. Invesco Ltd. now owns 20,940 shares of the company’s stock valued at $390,000 after purchasing an additional 4,962 shares during the period. Alliancebernstein L.P. lifted its position in shares of Dianthus Therapeutics by 14.5% during the second quarter. Alliancebernstein L.P. now owns 1,174,822 shares of the company’s stock worth $21,887,000 after purchasing an additional 149,200 shares in the last quarter. Finally, Raymond James Financial Inc. acquired a new position in shares of Dianthus Therapeutics during the second quarter worth $27,000. 47.53% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Dianthus Therapeutics

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 16,167 shares of the business’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $110.38, for a total transaction of $1,784,513.46. Following the completion of the transaction, the senior vice president directly owned 3,833 shares of the company’s stock, valued at $423,086.54. The trade was a 80.84% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director Simon Read sold 2,778 shares of the company’s stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $117.55, for a total transaction of $326,553.90. Following the completion of the transaction, the director owned 2,778 shares of the company’s stock, valued at approximately $326,553.90. This trade represents a 50.00% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 260,554 shares of company stock worth $27,211,775 over the last 90 days. Corporate insiders own 3.02% of the company’s stock.

Dianthus Therapeutics Price Performance

Shares of NASDAQ DNTH opened at $105.61 on Tuesday. The firm has a market capitalization of $5.77 billion, a PE ratio of -25.45 and a beta of 1.22. Dianthus Therapeutics, Inc. has a 1-year low of $22.81 and a 1-year high of $117.88. The business’s fifty day moving average price is $103.96 and its two-hundred day moving average price is $87.71.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.85) by ($0.05). The firm had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. Equities research analysts expect that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

DNTH has been the subject of several analyst reports. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Truist Financial boosted their price objective on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. TD Cowen reissued a “buy” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $124.27.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.